SAN FRANCISCO -- Left atrial appendage occlusion (LAAO) at the time of transcatheter aortic valve replacement (TAVR) appeared as safe as TAVR alone, the WATCH-TAVR trial showed. For patients with ...

SAN ANTONIO -- The Society of Thoracic Surgeons (STS) made a big push for left atrial appendage (LAA) occlusion in updated guidelines for the surgical treatment of atrial fibrillation (Afib). In this ...

Concerns about the lack of balanced information provided about left atrial appendage (LAA) closure procedures on the web pages of top US hospitals have been raised by a new study. The researchers ...

Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

Please provide your email address to receive an email when new articles are posted on . A database review showed left atrial appendage closure with the Watchman device is safe in adults with HF and ...

Intracardiac echocardiography can be used to safely and effectively guide left atrial appendage occlusion (LAAO) with the Watchman FLX device (Boston Scientific), according to the results of ...

The current bias of medicine is strong. When we are in doubt, when evidence is sparse, doctors do more, not less. Internists prescribe, cardiologists implant, surgeons cut. We know what we know. So it ...

Abbott, a global healthcare leader, announced it has received CE Mark and Health Canada approval for its Amplatzer Steerable Delivery Sheath, which is used with the company's market-leading Amplatzer ...

SEATTLE — A unique partnership between Overlake’s Heart and Vascular Center and EvergreenHealth Heart Care is supporting patients on the Eastside with comprehensive heart care services. “It provides a ...

Johnson & Johnson MedTech has become the newest competitor in the left atrial appendage (LAA) market after acquiring Laminar. The deal has the New Brunswick, NJ-based company doling out about $400 ...